Takeda Pharmaceutical, a Japan-based drugs company, has agreed to buy one of its corporate venturing unit’s portfolio companies, Envoy Therapeutics, for up to $140m.

Takeda Ventures invested in Envoy’s $8m series A round in October 2009 and partnered with the developer of drugs for neurological and psychiatric diseases.

The other investors in the A round had been venture capital firm 5AM Ventures and Roche Venture Fund, the corporate venturing unit of the eponymous Switzerland-based drugs group.

Takeda had also extended…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?